Axiom Investors LLC DE Makes New Investment in Teva Pharmaceutical Industries Ltd. $TEVA

Key Points

• Axiom Investors LLC DE made a new investment in Teva Pharmaceutical Industries, acquiring over 2.1 million shares valued at approximately $33.4 million, representing 0.19% ownership.
• Several hedge funds significantly increased their stakes in Teva, with Harel Insurance increasing its position by nearly 197,885% to over 22 million shares valued at $338.9 million.
• Teva's recent earnings report showed an EPS of $0.66, beating analyst expectations, while the company projected a FY 2025 EPS guidance of 2.500-2.600.

Axiom Investors LLC DE acquired a new position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) in the first quarter, according to the company in its most recent filing with the SEC. The firm acquired 2,173,807 shares of the company's stock, valued at approximately $33,411,000. Axiom Investors LLC DE owned 0.19% of Teva Pharmaceutical Industries at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of TEVA. Harel Insurance Investments & Financial Services Ltd. lifted its position in shares of Teva Pharmaceutical Industries by 197,885.2% in the 1st quarter. Harel Insurance Investments & Financial Services Ltd. now owns 22,055,547 shares of the company's stock worth $338,989,000 after acquiring an additional 22,044,407 shares during the period. Duquesne Family Office LLC lifted its position in shares of Teva Pharmaceutical Industries by 65.4% during the 1st quarter. Duquesne Family Office LLC now owns 14,879,750 shares of the company's stock worth $228,702,000 after buying an additional 5,882,350 shares during the period. Allspring Global Investments Holdings LLC lifted its position in shares of Teva Pharmaceutical Industries by 472.8% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 6,283,688 shares of the company's stock worth $96,078,000 after buying an additional 5,186,592 shares during the period. Assenagon Asset Management S.A. lifted its position in shares of Teva Pharmaceutical Industries by 416.0% during the 1st quarter. Assenagon Asset Management S.A. now owns 5,983,928 shares of the company's stock worth $91,973,000 after buying an additional 4,824,247 shares during the period. Finally, Nuveen LLC bought a new position in shares of Teva Pharmaceutical Industries during the 1st quarter worth approximately $40,827,000. Institutional investors own 54.05% of the company's stock.

Wall Street Analyst Weigh In

Several research firms recently commented on TEVA. Wall Street Zen upgraded Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research report on Saturday, July 26th. JPMorgan Chase & Co. upgraded Teva Pharmaceutical Industries from a "neutral" rating to an "overweight" rating and raised their target price for the stock from $21.00 to $23.00 in a research report on Monday, May 12th. The Goldman Sachs Group began coverage on Teva Pharmaceutical Industries in a research report on Friday, June 6th. They set a "buy" rating and a $24.00 target price for the company. Truist Financial initiated coverage on Teva Pharmaceutical Industries in a research report on Wednesday, May 28th. They set a "buy" rating and a $25.00 target price for the company. Finally, UBS Group dropped their price target on Teva Pharmaceutical Industries from $24.00 to $23.00 and set a "buy" rating for the company in a report on Thursday, June 26th. Two investment analysts have rated the stock with a Strong Buy rating and six have given a Buy rating to the stock. According to data from MarketBeat.com, Teva Pharmaceutical Industries currently has a consensus rating of "Buy" and a consensus price target of $24.71.

Insider Buying and Selling at Teva Pharmaceutical Industries

In other news, insider Eric A. Hughes sold 52,742 shares of Teva Pharmaceutical Industries stock in a transaction on Friday, August 1st. The stock was sold at an average price of $15.16, for a total value of $799,568.72. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Placid Jover sold 6,053 shares of Teva Pharmaceutical Industries stock in a transaction on Friday, August 1st. The shares were sold at an average price of $15.16, for a total value of $91,763.48. Following the completion of the sale, the insider directly owned 6,774 shares of the company's stock, valued at $102,693.84. This trade represents a 47.19% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.55% of the stock is currently owned by company insiders.

Teva Pharmaceutical Industries Trading Up 2.5%

TEVA stock opened at $18.94 on Monday. The business has a fifty day moving average price of $17.04 and a 200 day moving average price of $16.39. Teva Pharmaceutical Industries Ltd. has a fifty-two week low of $12.47 and a fifty-two week high of $22.80. The stock has a market capitalization of $21.72 billion, a price-to-earnings ratio of -118.35, a P/E/G ratio of 1.12 and a beta of 0.72. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.06 and a quick ratio of 0.77.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last released its earnings results on Wednesday, July 30th. The company reported $0.66 EPS for the quarter, beating the consensus estimate of $0.64 by $0.02. The company had revenue of $4.18 billion during the quarter, compared to analysts' expectations of $4.34 billion. Teva Pharmaceutical Industries had a positive return on equity of 46.10% and a negative net margin of 0.95%.The business's revenue for the quarter was up .3% on a year-over-year basis. During the same period last year, the firm earned $0.61 EPS. Teva Pharmaceutical Industries has set its FY 2025 guidance at 2.500-2.600 EPS. Analysts expect that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current fiscal year.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.